Erythropoietin can promote survival of cerebral cells by downregulating Bax gene after traumatic brain injury in rats

Neurology India

Volumn 57, Issue 6, 2009, Pages 722-728

  Liao, Z B ^a   Jiang, G Y ^a   Tang, Z H ^a   Zhi, X G ^a   Sun, X C ^a   Tang, W Y ^a   Wu, M J ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Bax; Cell death; RhEPO; Traumatic brain injury

Indexed keywords

MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; IMAGE ANALYSIS; IMMUNOFLUORESCENCE; NERVE CELL NECROSIS; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHAM PROCEDURE; TRAUMATIC BRAIN INJURY; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; BRAIN INJURIES; CELL SURVIVAL; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ERYTHROPOIETIN; HUMANS; IN SITU NICK-END LABELING; RATS; RATS, WISTAR; RNA, MESSENGER; TIME FACTORS;

EID: 77249089313     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.59466     Document Type: Article

References (48)

1. O'Barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T, et al. Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 2001;166:4154-4162
2. Alexander JJ, Jacob A, Bao L, Macdonald RL, Quigg RJ. Complement-dependent cell death and inflammatory gene changes in murine lupus cerebritis. J Immunol 2005;175:8312-8319
3. Bellander BM, Singhrao SK, Ohlsson M, Mattsson P, Svensson M. Complement activation in the human brain after traumatic head injury. J Neurotrauma 2001;18:1295-1311
4. Ohlsson M, Bellander BM, Langmoen IA, Svensson M. Complement activation following optic nerve crush in the adult rat. J Neurotrauma 2003;20:895-904.
5. McArthur DL, Chute DJ, Villablanca JP. Moderate and severe traumatic brain injury: Epidemiologic, imaging and neuropathologic perspectives. Brain Pathol 2004;14:185-194
6. Zhang X, Chen Y, Jenkins LW, Kochanek PM, Clark RS. Bench-tobedside review: Cell death/programmed cell death triggered by traumatic brain injury. Crit Care 2005;9:66-75.
7. Celik M, Gökmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, et al. Erythropoietin prevents motor neuron cell death and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U.S.A 2002;99:2258-2263
8. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature (Lond) 2001;412:641-647
9. Faden AI. Neuroprotection and traumatic brain injury: Theoretical option or realistic proposition. Curr Opin Neurol 2002;15:707-712
10. Feeney DM, Boyeson MG, Linn RT, Murray HM, Dail WG. Responses to cortical injury: I. Methodology and local effects of contusions in the rat. Brain Res 1981;211:67-77.
11. Golarai G, Greenwood AC, Feeney DM, Connor JA. Physiological and structural evidence for hippocampal involvement in persistent seizure susceptibility after traumatic brain injury. J Neurosci 2001;21:8523-8537
12. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U.S.A 2002;99: 9450-9455
13. Kang JQ, Chong ZZ, Maiese K. Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol Pharmacol 2003;64:557-569
14. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998;95:4635-4640
15. Stefanis L. Caspase-dependent and -independent neuronal death: Two distinct pathways to neuronal injury. Neuroscientist 2005;11:50-62.
16. Sola A, Rogido M, Lee BH, Genetta T, Wen TC. Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr Res 2005;57:481-487
17. Knoblach SM, Alroy DA, Nikolaeva M, Cernak I, Stoica BA, Faden AI. Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. J Cereb Blood Flow Metab 2004;24:1119-1132
18. Liu CL, Siesjo BK, Hu BR. Pathogenesis of hippocampal neuronal death after hypoxia-ischemia changes during brain development. Neuroscience 2004;127:113-123
19. Ohlsson M, Havton LA. Complement activation after lumbosacral ventral root avulsion injury. Neurosci Lett 2005;394:179-183
20. Sun Y, Zhou C, Polk P, Nanda A, Zhang JH. Mechanisms of erythropoietin- induced brain protection in neonatal hypoxia-ischemia rat model. J Cereb Blood Flow Metab 2004;24:259-270
21. Liao ZB, Zhi XG, Shi QH, He ZH. Recombinant human erythropoietin administration protects cortical neurons from traumatic brain injury in rats. Eur J Neurol 2008;15:140-149
22. Wei L, Ying DJ, Cui L, Langsdorf J, Yu SP. Necrosis, cell death and hybrid death in the cortex and thalamus after barrel cortex ischemia in rats. Brain Res 2004;1022:54-61.
23. Yatsiv I, Grigoriadis N, Simeonidou C, Stahel PF, Schmidt OI, Alexandrovitch AG, et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal cell death and inflammation in a rodent model of experimental closed head injury. Faseb J 2005;12:1701-1703
24. Chang YS, Mu D, Wendland M, Sheldon RA, Vexler ZS, McQuillen PS, et al. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr Res 2005;58:106-111
25. Chen S, Pickard JD, Harris NG. Time course of cellular pathology after controlled cortical impact injury. Exp Neurol 2003;182:87-102.
26. Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol 2003;138:1107-1118
27. Casarsa C, de Luigi A, Pausa M, de Simoni MG, Tedesco F. Intracerebroventricular injection of terminal complement complex causes inflammatory reaction in the rat brain. Eur J Immunol 2003;33:1260-1270
28. Xiong ZQ, Qian W, Suzuki K, McNamara JO. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J Neurosci 2003;23:955-960
29. Kyrkanides S, O'Banion MK, Whiteley PE, Daeschner JC, Olschowka JA. Enhanced glial activation and expression of specific CNS inflammation-related molecules in aged versus young rats following cortical stab injury. J Neuroimmunol 2001;119:268-277
30. Rancan M, Morganti-Kossmann MC, Barnum SR, Saft S, Schmidt OI, Ertel W, et al. Central nervous system-targeted complement inhibition mediates neuroprotection after closed head injury in transgenic mice. J Cereb Blood Flow Metab 2003;23:1070-1074
31. Cole DS, Hughes TR, Gasque P, Morgan BP. Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis. Mol Immunol 2006;43:1953-1964
32. Gaetz M. The neurophysiology of brain injury. Clin Neurophysiol 2004;115:4-18.
33. Eldadah BA, Faden AI. Caspase pathways, neuronal cell death, and CNS injury. J Neurotrauma 2000;17:811-829
34. Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol 2004;14:215-222
35. Wong J, Hoe NW, Zhiwei F, Ng I. Cell death and traumatic brain injury. Neurocrit Care 2005;3:177-182
36. Stahel PF, Kariya K, Shohami E, Barnum SR, Eugster H, Trentz O, et al. Intracerebral complement C5a receptor (CD88) expression is regulated by TNF and lymphotoxin-alpha following closed head injury in mice. J Neuroimmunol 2000;109:164-172
37. Pillay NS, Kellaway LA, Kotwal GJ. Administration of vaccinia virus complement control protein shows significant cognitive improvement in a mild injury model. Ann N Y Acad Sci 2005;1056:450-461
38. Leinhase I, Schmidt OI, Thurman JM, Hossini AM, Rozanski M, Taha Me, et al. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp Neurol 2006;199:454-464
39. Stahel PF, Barnum SR. The role of the complement system in CNS inflammatory diseases. Expert Rev Clin Immunol 2006;2:445-456
40. Holers VM, Thurman JM. The alternative pathway of complement in disease: Opportunities for therapeutic targeting. Mol Immunol 2004;41:147-152
41. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 2003;170:1517-1523
42. Thurman JM, Lucia MS, Ljubanovic D, Holers VM. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int 2005;67:524-530
43. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006;176:1305-1310
44. Williams S, Raghupathi R, MacKinnon MA, McIntosh TK, Saatman KE, Graham DI. In situ DNA fragmentation occurs in white matter up to 12 months after head injury in man. Acta Neuropathol 2001;102:581-590
45. Marciano PG, Brettschneider J, Manduchi E, Davis JE, Eastman S, Raghupathi R, et al. Neuron-specific mRNA complexity responses during hippocampal cell death after traumatic brain injury. J Neurosci 2004;24:2866-2876
46. Elward K, Griffiths M, Mizuno M, Harris CL, Neal JW, Morgan BP, et al. CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem 2005;280:36342-36354
47. Nataf S, Carroll SL, Wetsel RA, Szalai AJ, Barnum SR. Attenuation of experimental autoimmune demyelination in complement- deficient mice. J Immunol 2000;165:5867-5873
48. Felderhoff-Mueser U, Sifringer M, Pesditschek S, Kuckuck H, Moysich A, Bittigau P, et al. Pathways leading to apoptotic neurodegeneration following trauma to the developing brain. Neurobiol Dis 2002;11:231-245 (Pubitemid 36135688)